Bright Minds Bioscience: A Deep Dive

Today we are diving into a firm focused on mental health, whom is also a recently Nasdaq-listed Psychedelic Stock, Bright Minds Biosciences (NASDAQ: DRUG). The firm is focused on the development of second generation psychedelic pharmaceuticals for treatment of neuropsychiatric disorders, which will maintain IP protections, unlike its peers whom are largely focused on first generation psychedelic compounds.

As of the last quarter, the company had $22M cash on the balance sheet with only 12M shares outstanding. The Company leverages its world-class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs, with members of its scientific team including renowned scientists like Dr. Alan Kozikowski and Dr. Gideon Shapiro.


FULL DISCLOSURE: Bright Minds Biosciences is a client of Canacom Group, the parent company of The Deep Dive. The company has been compensated to cover Bright Minds Biosciences on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. We may buy or sell securities in the company at any time. Always do additional research and consult a professional before purchasing a security.

Video Articles

Goliath Resources Hits 10.60 g/t Gold Over 22.82 Metres, Highest Grade Results In Third Distinct Rock Package At Surebet Discovery

Four Countries Control the Fertilizer That Feeds the World | Sage Potash

$10,000 Gold Is Just A Question of Time | Florian Grummes

Recommended

ESGold Outlines $24.3 Million NPV For Tailings Reprocessing Project

First Majestic Encounters 711 g/t Silver Equivalent Over 8.0 Metres In Ongoing Exploration At Los Gatos

Related News

Bright Minds Biosciences: Corporate Overview

Bright Minds Biosciences Inc. (CSE: DRUG) is a small-cap preclinical biosciences company that is attempting to...

Monday, May 31, 2021, 02:43:00 PM

Psychedelics: The Eight Capital Primer

Eight Capital recently produced a primer on the psychedelic sector saying that the companies are...

Monday, June 14, 2021, 03:38:00 PM

Bright Minds Expands Leadership, Scientific Advisory Teams

Bright Minds Biosciences (CSE: DRUG) this morning enhanced its leadership team. The company appointed two...

Tuesday, April 27, 2021, 08:44:04 AM

Bright Minds Biosciences Proprietary Compound Shows Reduction Of Seizures In Pre-Clinical Studies

Bright Minds Biosciences (CSE: DRUG) this morning announced preliminary results from an ongoing study being...

Wednesday, August 18, 2021, 08:54:44 AM

Bright Minds: Focusing On Second Generation Psychedelic Compounds – The Daily Dive

Starting off this week on the Daily Dive is that of Dr Gideon Shapiro, whom...

Monday, June 21, 2021, 01:30:00 PM